PRMA Insights: The Roadmap to Pricing and Reimbursement Success
Authors of the psoriasis report
The ground-breaking psoriasis report is written by a team of industry experts and validated by payers and KOLs in every market. Our industry experts bring global hands-on experience of the strategic, commercial, technical and scientific market access challenges faced across the pharmaceutical and healthcare industries today.
 |
David Sykes David Sykes is the founding partner of PRMA Consulting. He has over fourteen years experience working in the field of pricing and reimbursement, market access and health outcomes and has held senior leadership roles at Lilly and J&J. David has developed European and global pricing, reimbursement and market access programmes to quantify, capture and communicate product value, including several launch compounds across multiple therapy areas. David has published extensively in the area of health economics. |
Sotiria Papanicolaou Prior to Janssen-Cilag, Sotiria was a member of the European Health Outcomes Research group of Eli Lilly, developing health economics and outcomes strategies to support local pricing & reimbursement negotiations for new products. |
 |
Dr. Mark Larkin Dr. Mark Larkin has over ten years experience working in strategy consulting and finance. Mark has strategy development experience across a broad range of therapeutic areas, at both the European and global levels. Mark has extensive experience of advising North American and European developers on pricing, reimbursement and market access strategies, either for in-house launches or in support of business development objectives. |
 |
Shkun Chadda Shkun has over nine years experience working in health outcomes within both the pharmaceutical and consultancy sectors. She has worked in health outcomes groups at a national, regional and global level in blue chip pharmaceutical companies and as the health outcomes lead on regional cross functional teams for several oncology products. Shkun has been responsible for multiple NICE and SMC submissions in the oncology area. |
 |
Dr. Marcus Healey, MBA Dr. Marcus Healey, MBA is the Principal Medical Writer for PRMA Consulting. Marcus has over eight years experience in medical communications and twenty years of writing experience in the US and abroad across numerous therapeutic areas. Marcus was the co-author and editor of three books with major publishers, has authored thirteen publications in scientific journals, and delivered over twenty scientific presentations. |
 |
Dr. Meredith Edwards Dr. Meredith Edwards is a medical doctor who has practised in Australia and the UK across several clinical specialisations. After moving to France five years ago, Meredith has been working in the pharmaceutical industry as Director of Medical Affairs in a Clinical Research Organisation which included authoring reports for regulatory submission, and in the field of strategic and management consulting where she was involved in developing product launch plans, corporate strategy, drug approval regulatory strategy definition, expert interviews, clinical trial analysis, and hospital program and strategy formulation. She has published several articles in both scientific and industry journals. |
 |
Steve Crowley Steve has twenty years experience in health economic evaluation. He has worked in a number of leading pharmaceutical companies including GlaxoWellcome, Merck and Janssen-Cilag. He has strong Asia Pacific experience with board (Management Team) positions at a top ten pharmaceutical company in Australia and Asia-Pacific. He has experience in building market access capabilities across the Asia-Pacific region. |
 |
Alexander (Sandy) Simpson Sandy Simpson has over twenty years experience in the pharmaceutical industry. He has held senior medical positions both in the UK and Europe with Eli Lilly, and has been directly involved in the launches of multiple new compounds. From 2003 until 2009 he was a member of the Scottish Medicines Consortium, representing the Association of the British Pharmaceutical Association (ABPI). |
 |
Dr. Jan Geldmacher Dr. Jan Geldmacher has over 30 years experience of the German healthcare system. A qualified physician, Dr. Geldmacher has been a member of the Drug committee of the GBA (Federal Joint Committee of SHI-physicians and SHI) since 1997, a member of the Expert Advisory Committee for prescriptive-only products of the German Health Ministry since 1996, a member of the Drug commission of the German Medical Association (AKDÄ) since 1994 and a representative of the AKDÄ as committee member for drug safety of the Federal Institute for Drug and Medicinal Products (BfArM) since 1994. |
| Vanessa Mirsky Vanessa has over ten years healthcare and life sciences commercialization strategy consulting experience, with a strong background in managed markets, including reimbursement dynamics among public and private payers in the US. Vanessa has significant consulting experience with multinational pharmaceutical companies, having worked for large consulting firms, such as Deloitte, CSC and Publicis Healthcare, as well as several small boutique firms in the US. Vanessa has significant experience in oncology and biologics. |
| Dr. Luis Prieto Dr. Luis Prieto, MBA, MPH has held positions as Senior Health Economist at Serono, Spain and Portugal and Senior Health Outcomes Manager at Eli Lilly & Co., Spain. Luis has significant experience of leading pricing and reimbursement submissions in Spain and working with the regions to achieve market access across a range of therapy areas. |
Find out more about the psoriasis report:
The report delivers Scope of the report Authors of the reportprmainsights